Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.59 USD | +5.58% |
|
+10.21% | -6.68% |
06-24 | Japan's Nikkei ends choppy session on stronger note | RE |
06-24 | Japan's Nikkei squeezes out gains in choppy session | RE |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analyst opinion has improved significantly over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The firm trades with high earnings multiples: 26.88 times its 2024 earnings per share.
- Based on current prices, the company has particularly high valuation levels.
- The company appears highly valued given the size of its balance sheet.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.68% | 55.2B | - | ||
+55.19% | 801B | C+ | ||
+47.26% | 631B | B | ||
-6.09% | 359B | C+ | ||
+21.92% | 337B | B- | ||
+18.40% | 245B | B+ | ||
+3.64% | 231B | A+ | ||
+12.98% | 219B | B- | ||
+10.86% | 171B | C+ | ||
-2.78% | 161B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4519 Stock
- CHGC.Y Stock
- Ratings Chugai Pharmaceutical Co., Ltd.